Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin’s Lymphoma
Study Information
Alliance Study ID: CALGB-50103
NCT Study ID (ClinicalTrials.gov): NCT00032019
Alliance Committee: Lymphoma
Disease or Cancer Type: Lymphoma
Alliance Study Chair: Wyndham H. Wilson, MD, PhD
Status: COMPLETED
Study Description
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining rituximab with combination chemotherapy may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining rituximab with combination chemotherapy in treating patients who have previously untreated non-Hodgkin’s lymphoma.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information